

**IASLC WCLC 2018 SYMPOSIUM**

# Refining the Focus in Lung Cancer: New Data and Emerging Biomarkers

**Sunday, 23 September 2018 | 14:30–16:00**

105 MTCC

Metro Toronto Convention Centre, North Building

*Toronto, ON, Canada*

This program was approved by the IASLC 19th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 19th World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC.

This program has received an educational grant and in-kind support from Bristol-Myers Squibb Company.

# Refining the Focus in Lung Cancer: New Data and Emerging Biomarkers

**Sunday, 23 September 2018 | 14:30–16:00**

105 MTCC

Metro Toronto Convention Centre, North Building

Toronto, ON, Canada

## SCIENTIFIC PLANNING COMMITTEE

---



**Rosalyn Juergens, MD, PhD**

McMaster University  
*Hamilton, ON, Canada*

**Meeting Chair**



**Solange Peters, MD, PhD**

University of Lausanne  
*Lausanne, Switzerland*



**Matthew Hellmann, MD**

Memorial Sloan Kettering Cancer Center  
*New York, NY, United States*



**Vera Hirsh, MD**

McGill University Health Center  
*Montreal, QC, Canada*

## LEARNING OBJECTIVES

---

1. Identify the unmet needs in NSCLC and the advantages of chemo-sparing approaches
2. Review and interpret clinical data for I-O combination therapies in 1L NSCLC
3. Describe the biomarker landscape and emerging patient segmentation in lung, including PD-L1 and TMB
4. Recognize the unmet needs and I-O data in SCLC and mesothelioma
5. Define the safety profiles with monotherapies and combination therapies